The patient was taking metformin before this hospitalization. To facilitate better glucose control, the patient has been switched to insulin therapy while hospitalized. The patient asks the nurse why it is so important to time meals with the insulin injection and to give him an example of a long-acting insulin. The nurse will tell the patient that an example of a long-acting insulin is:

Choice A rationale Insulin glulisine is a rapid-acting insulin analog. Its onset of action is typically 10 to 15 minutes, with a peak effect in about one hour. This makes it suitable for use immediately before or with a meal to manage the postprandial glucose spike, but it does not provide the prolonged glucose-lowering effect characteristic of long-acting insulins. Choice B rationale Insulin isophane suspension, also known as NPH insulin, is an intermediate-acting insulin. It has a slower onset of action than rapid or short-acting insulins and provides glucose control for a longer duration, typically up to 18 hours. However, its duration is shorter than that of true long-acting insulins, and it has a distinct peak effect. Choice C rationale Insulin detemir is a long-acting insulin analog. It is designed to provide a steady, peakless, and prolonged glucose-lowering effect for up to 24 hours. Its mechanism involves binding to albumin in the bloodstream, which slows its absorption and breakdown, ensuring a continuous and stable basal insulin level. Choice D rationale Insulin aspart is a rapid-acting insulin analog. Similar to insulin glulisine, it has a rapid onset of action, typically within 10 to 20 minutes, and a peak effect around one to three hours. It is used to cover the glucose increase from meals and is not an example of a long-acting insulin, which provides basal coverage.